about
Rotenone, paraquat, and Parkinson's diseasePimozide for tics in Tourette's syndromePimozide for tics in Tourette syndromeSolvent exposures and Parkinson disease risk in twinsOccupation and risk of parkinsonism: a multicenter case-control studyProtective glove use and hygiene habits modify the associations of specific pesticides with Parkinson's diseaseThe complexities of hormonal influences and risk of Parkinson's diseaseGenetic modification of the association of paraquat and Parkinson's diseaseIs there seasonal variation in risk of Parkinson's disease?Longitudinal quantitative MRI in multiple system atrophy and progressive supranuclear palsy.Regular Exercise, Quality of Life, and Mobility in Parkinson's Disease: A Longitudinal Analysis of National Parkinson Foundation Quality Improvement Initiative DataThe curious case of phenocopies in families with genetic Parkinson's disease.Piecing together the puzzle of progression and mortality in Parkinson's disease.Author reply to Holford, Vu and Nutt regarding 'Piecing together the puzzle of progression and mortality in Parkinson's disease'.Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study.Urate as a predictor of the rate of clinical decline in Parkinson disease.Initiating dopaminergic treatment in Parkinson's disease.Predicting motor decline and disability in Parkinson disease: a systematic review.Colonic mucosal a-synuclein lacks specificity as a biomarker for Parkinson disease.Peptidoglycan recognition protein genes and risk of Parkinson's disease.Therapeutic development paths for cognitive impairment in Parkinson's disease: report of a regulatory roundtableMichael J. Fox Foundation LRRK2 Consortium: geographical differences in returning genetic research data to study participants.Clinical correlations with Lewy body pathology in LRRK2-related Parkinson diseaseHead injury, α-synuclein Rep1, and Parkinson's disease.Fixing the broken system of genetic locus symbols: Parkinson disease and dystonia as examples.Measuring mild cognitive impairment in patients with Parkinson's diseaseProtocol for a systematic review of prognosis after mild traumatic brain injury: an update of the WHO Collaborating Centre Task Force findingsOutcome measures for clinical trials in Parkinson's disease: achievements and shortcomings.Antipsychotic Use and Physical Morbidity in Parkinson Disease.Antipsychotic use in older adults with Parkinson's disease.Environmental and occupational risk factors for progressive supranuclear palsy: Case-control study.Inflammatory profile in LRRK2-associated prodromal and clinical PDInvited article: changing concepts in Parkinson disease: moving beyond the decade of the brain.Association of Antipsychotic Use With Mortality Risk in Patients With Parkinson Disease.Dietary fat intake, pesticide use, and Parkinson's disease.Another face of placebo: the lessebo effect in Parkinson disease: meta-analyses.Investigation of c9orf72 in 4 neurodegenerative disorders.Genetics meets environment: evaluating gene-environment interactions in neurologic diseases.Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic.Parkinson's disease subtypes: lost in translation?
P50
Q22241595-070B979A-8FD3-489A-BA69-E06B68480811Q24241313-982CDE32-CD5E-444C-A283-916E823E4531Q24243028-F840EF87-BBA0-4AD3-919C-27ECA2518691Q24613285-6029F6FD-B22F-48C8-8DE6-DE695238D2BFQ28258493-BA6B413F-4CEB-4194-BD4C-8BE274020AB2Q28384644-81854980-1F27-4026-BF51-F569FF2B6E5DQ28389039-08CCC41F-F3CE-44CF-9FB1-93386CEC52D2Q28394396-4487B047-06DE-4163-85D7-36595A8B877DQ30361489-B2B9897F-BFBA-46B8-9EE6-73A893B30B81Q30696088-ACD0869A-AC49-41A8-BC03-37C140B22051Q31142926-342D755A-38DA-4D34-B341-CEA29317EB76Q33351731-74B54453-580B-47EF-ABCF-6245F3C61952Q33353479-8A0870AC-3CC3-4E78-9801-BFD2E5CC26FFQ33354356-E3292CF3-8044-42E3-9439-E49169875708Q33869831-8B0FBC56-B07A-4D7E-B99D-D079DE0A758FQ34019732-1A72EEC3-68B7-4FBB-8CA7-75C4543C8801Q34424795-21FD41F5-B358-4A6F-8B79-C28CF2CE3627Q34998248-892CBC23-0761-4D31-B894-819802E0EF7AQ35106243-8C8412E7-B6C9-4FD8-AAAE-197AA7027A97Q35170538-18214A06-0A50-49AC-A21B-0F80464B9CE8Q35211545-6535ECC4-6164-49FF-8A4C-969D26D1D8E8Q35219481-2AF8F315-C80E-46EB-B237-B9CEBE1FD3F9Q35442728-41C07EA0-57C4-4E27-8512-7F60D0096C17Q35726904-7AD212C5-872A-48E8-90C6-7797CC0A49C4Q35846517-B4503620-6903-40C1-9ACB-C1B6ECE9F006Q35914968-BB6AD766-530D-40C7-AEDE-E9B46093767BQ35958042-43B78E32-2701-4B3F-AF19-749FD727615AQ36106907-DB348AD7-B224-4FA0-B192-8A21CCBD8500Q36297406-F338E71B-61DF-463A-B599-04EF60AE4652Q36675301-B8F5CB2F-18D9-4A30-B3F1-1EABD9CDCA87Q36885365-CB11A96F-813E-498D-A303-42ECC5BB377FQ36934387-00FEF924-2F94-4658-B67C-8852B162C963Q37168105-14376B45-7332-48E7-AC81-8A08C746D945Q37505818-22F2497B-644B-4302-AADA-31475C9A9A14Q37606627-E77E2A3B-DAEE-4D41-913B-4158D18D4325Q37725888-4D7BB90D-D46D-41A0-B86D-330A28CE4CB2Q37734768-500531C2-B3C6-4AAE-B210-5410AA8EE9A4Q37977846-B4687C57-014C-4897-81BE-0F1D1E36B6D7Q38039066-FDECCB5D-4111-48AD-8326-3E8900FEE545Q38041083-5038E6A2-E657-477D-BDA6-9EEE74B1754E
P50
description
onderzoeker
@nl
name
Connie Fernández-Cid Marras
@ast
Connie Fernández-Cid Marras
@en
Connie Fernández-Cid Marras
@es
Connie Fernández-Cid Marras
@nl
type
label
Connie Fernández-Cid Marras
@ast
Connie Fernández-Cid Marras
@en
Connie Fernández-Cid Marras
@es
Connie Fernández-Cid Marras
@nl
altLabel
Connie Marras
@en
prefLabel
Connie Fernández-Cid Marras
@ast
Connie Fernández-Cid Marras
@en
Connie Fernández-Cid Marras
@es
Connie Fernández-Cid Marras
@nl